Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Proteins interacting with the third cytoplasmic loop of dopamine D2 and D3 receptors

Journal of Pharmacological Sciences

Volumn 114, Issue 1, 2010, Pages 25-31

  Shioda, Norifumi ^a   Takeuchi, Yusuke ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Aoba Hospital   (Japan)

Author keywords

Alternative splicing variant; Catalepsy; Heart type fatty acid binding protein

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALMODULIN; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; FATTY ACID BINDING PROTEIN; FILAMIN A; HEART TYPE FATTY ACID BINDING PROTEIN; LEUCINE ZIPPER PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; N ETHYLMALEIMIDE SENSITIVE FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROSTATE APOPTOSIS RESPONSE 4; PROTEIN 4.1N; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; COGNITION; CYTOPLASM; DOPAMINERGIC SYSTEM; DRUG RESEARCH; EMOTION; GENE DELETION; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STEREOTYPY;

EID: 77957935835     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R02FM     Document Type: Review

References (35)

1. Missale C, Nash R, Robinson SW, Jaber M, Caron MG. Dopamine receptors from structure to function. Physiol Rev. 1998;78:189-225.
2. Sidhu A, Niznik HB. Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci. 2000;18:669-677.
3. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, et al. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 1989;8:4025-4034.
4. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. A structural polymorphism of human dopamine D2 receptor, D2 (Ser311→Cys). Biochem Biophys Res. Commun. 1993;196:1369-1375.
5. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet. 1994;343:703-704.
6. Laurent C, Bodeau-Pean S, Campion D, d'Amato T, Jay M, Dollfus S, et al. No major role for the dopamine D2 receptor Ser→Cys311 mutation in schizophrenia. Psychiatr Genet. 1994;4:229-230.
7. Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem. 1996;271:26013-26017.
8. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007;104:20552-20557.
9. Richtand NM. Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology. 2006;31:2368-2375.
10. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem. 2000;275:32672-32680.
11. Rhoads AR, Friedberg F. Sequence motifs for calmodulin recognition. FASEB J. 1997;11:331-340.
12. Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, et al. Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron. 2009;61:425-438.
13. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci. 1990;11:290-296.
14. Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, et al. Modulation of D2R-NR2B interactions in response to cocaine. Neuron. 2006;52:897-909.
15. Ouimet CC, McGuinness TL, Greengard P. Immunocytochemical localization of calcium/calmodulin-dependent protein kinase II in rat brain. Proc Natl Acad Sci U S A. 1984;81:5604-5608.
16. 2+/calmodulin- dependent protein kinase II. J Biol Chem. 1993;268:7863-7867.
17. Lin R, Canfield V, Levenson R. Dominant negative mutants of filamin A block cell surface expression of the D2 dopamine receptor. Pharmacology. 2002;66:173-181.
18. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci U S A. 2001;98:5258-5263.
19. Walensky LD, Blackshaw S, Liao D, Watkins CC, Weier HU, Parra M, et al. A novel neuron-enriched homolog of the erythrocyte membrane cytoskeletal protein 4.1. J Neurosci. 1999;19:6457-6467.
20. Binda AV, Kabbani N, Lin R, Levenson R. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol. 2002;62:507-513.
21. Sells SF, Wood DP Jr, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ. 1994;5:457-466.
22. Park SK, Nguyen MD, Fischer A, Luke MP, Affarel B, Dieffenbach PB, et al. Par-4 links dopamine signaling and depression. Cell. 2005;122:275-287.
23. Hanson PI, Otto H, Barton N, Jahn R. The N-ethylmaleimidesensitive fusion protein and alpha-SNAP induce a conformational change in syntaxin. J Biol Chem. 1995;270:16955-16961.
24. Nishimune A, Isaac JT, Molnar E, Noel J, Nash SR, Tagaya M, et al. NSF binding to GluR2 regulates synaptic transmission. Neuron. 1998;21:87-97.
25. Zou S, Li L, Pei L, Vukusic B, Van Tol HH, Lee FJ, et al. Protein-protein coupling/uncoupling enables dopamine D2 receptor regulation of AMPA receptor-mediated excitotoxicity. J Neurosci. 2005;25:4385-4395.
26. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, Liu F. Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 2007;26:2127-2136.
27. Takeuchi Y, Fukunaga K. Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J Neurochem. 2003;85:1064-1074.
28. Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaga K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci. 2010;30:3146-3155.
29. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res. 1995;29:227-232.
30. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62:195-204.
31. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006;56:159-164.
32. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res. 1999;40:211-225.
33. Owada Y, Yoshimoto T, Kondo H. Spatio-temporally differential expression of genes for three members of fatty acid-binding proteins in developing and mature rat brains. J Chem Neuroanat. 1996;12:113-122.
34. Arai Y, Funatsu N, Numayama-Tsuruta K, Nomura T, Nakamura S, Osumi N. Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci. 2005;25:9752-9761.
35. Watanabe A, Toyota T, Owada Y, Hayashi T, Iwayama Y, Matsumata M, et al. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol. 2007;5:e297.